WEST PHARMACEUTICAL SERVICES, INC. Excess Tax Benefit from Share-based Compensation, Financing Activities
WEST PHARMACEUTICAL SERVICES, INC. (WST) reported Excess Tax Benefit from Share-based Compensation, Financing Activities of $0 for the 12-month period ending 2018-12-31, per its 10-K filed 2019-02-28.
Discontinued › Notes › Compensation Related Costs
us-gaap:ExcessTaxBenefitFromShareBasedCompensationFinancingActivities · last filed 2019-02-28
- WEST PHARMACEUTICAL SERVICES, INC. excess tax benefit from share-based compensation, financing activities for the quarter ending 2017-12-31 was $0.00, a 100.00% decline year-over-year.
- WEST PHARMACEUTICAL SERVICES, INC. excess tax benefit from share-based compensation, financing activities for the quarter ending 2017-09-30 was $0.00, a 100.00% decline year-over-year.
- WEST PHARMACEUTICAL SERVICES, INC. excess tax benefit from share-based compensation, financing activities for the quarter ending 2017-06-30 was $0.00, a 100.00% decline year-over-year.
- WEST PHARMACEUTICAL SERVICES, INC. excess tax benefit from share-based compensation, financing activities for the quarter ending 2017-03-31 was $0.00, a 100.00% decline year-over-year.
- WEST PHARMACEUTICAL SERVICES, INC. excess tax benefit from share-based compensation, financing activities for fiscal 2018 was $0.00.
- WEST PHARMACEUTICAL SERVICES, INC. excess tax benefit from share-based compensation, financing activities for fiscal 2017 was $0.00, a 100.00% decline from fiscal 2016.
- WEST PHARMACEUTICAL SERVICES, INC. excess tax benefit from share-based compensation, financing activities for fiscal 2016 was $18.20M, a 100.00% increase from fiscal 2015.
- WEST PHARMACEUTICAL SERVICES, INC. excess tax benefit from share-based compensation, financing activities for fiscal 2015 was $9.10M, a 15.19% increase from fiscal 2014.
| Period end | Excess Tax Benefit from Share-based Compensation, Financing Activities 3 month | Excess Tax Benefit from Share-based Compensation, Financing Activities 6 month | Excess Tax Benefit from Share-based Compensation, Financing Activities 9 month | Excess Tax Benefit from Share-based Compensation, Financing Activities 12 month |
|---|---|---|---|---|
| 2018-12-31 | $0.00 10-K · filed 2019-02-28 | |||
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-28 | $0.00 derived: sum of 2 quarters · filed 2019-02-28 | $0.00 derived: sum of 3 quarters · filed 2019-02-28 | $0.00 10-K · filed 2019-02-28 |
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-10-31 | $0.00 derived: sum of 2 quarters · filed 2017-10-31 | $0.00 10-Q · filed 2017-10-31 | $4.30M derived: sum of 4 quarters · filed 2019-02-28 |
| 2017-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-01 | $0.00 10-Q · filed 2017-08-01 | $4.30M derived: sum of 3 quarters · filed 2019-02-28 | $5.10M derived: sum of 4 quarters · filed 2019-02-28 |
| 2017-03-31 | $0.00 10-Q · filed 2017-05-05 | $4.30M derived: sum of 2 quarters · filed 2019-02-28 | $5.10M derived: sum of 3 quarters · filed 2019-02-28 | $7.20M derived: sum of 4 quarters · filed 2019-02-28 |
| 2016-12-31 | $4.30M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-28 | $5.10M derived: sum of 2 quarters · filed 2019-02-28 | $7.20M derived: sum of 3 quarters · filed 2019-02-28 | $18.20M 10-K · filed 2019-02-28 |
| 2016-09-30 | $800.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-10-31 | $2.90M derived: sum of 2 quarters · filed 2017-10-31 | $13.90M 10-Q · filed 2017-10-31 | $18.80M derived: sum of 4 quarters · filed 2018-02-26 |
| 2016-06-30 | $2.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-01 | $13.10M 10-Q · filed 2017-08-01 | $18.00M derived: sum of 3 quarters · filed 2018-02-26 | $18.70M derived: sum of 4 quarters · filed 2018-02-26 |
| 2016-03-31 | $11.00M 10-Q · filed 2017-05-05 | $15.90M derived: sum of 2 quarters · filed 2018-02-26 | $16.60M derived: sum of 3 quarters · filed 2018-02-26 | $17.20M derived: sum of 4 quarters · filed 2018-02-26 |
| 2015-12-31 | $4.90M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-26 | $5.60M derived: sum of 2 quarters · filed 2018-02-26 | $6.20M derived: sum of 3 quarters · filed 2018-02-26 | $9.10M 10-K · filed 2018-02-26 |
| 2015-09-30 | $700.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-10-31 | $1.30M derived: sum of 2 quarters · filed 2016-10-31 | $4.20M 10-Q · filed 2016-10-31 | $6.60M derived: sum of 4 quarters · filed 2017-02-28 |
| 2015-06-30 | $600.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-01 | $3.50M 10-Q · filed 2016-08-01 | $5.90M derived: sum of 3 quarters · filed 2017-02-28 | $7.70M derived: sum of 4 quarters · filed 2017-02-28 |
| 2015-03-31 | $2.90M 10-Q · filed 2016-05-06 | $5.30M derived: sum of 2 quarters · filed 2017-02-28 | $7.10M derived: sum of 3 quarters · filed 2017-02-28 | $8.10M derived: sum of 4 quarters · filed 2017-02-28 |
| 2014-12-31 | $2.40M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-28 | $4.20M derived: sum of 2 quarters · filed 2017-02-28 | $5.20M derived: sum of 3 quarters · filed 2017-02-28 | $7.90M 10-K · filed 2017-02-28 |
| 2014-09-30 | $1.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-02 | $2.80M derived: sum of 2 quarters · filed 2015-11-02 | $5.50M 10-Q · filed 2015-11-02 | |
| 2014-06-30 | $1.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-03 | $3.70M 10-Q · filed 2015-08-03 | ||
| 2014-03-31 | $2.70M 10-Q · filed 2015-05-06 | |||
| 2013-12-31 | $8.30M 10-K · filed 2016-02-26 | |||
| 2012-12-31 | $4.90M 10-K · filed 2015-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| DEXCOM INC (DXCM) | United States | $33.004B | 25.42 |
| Solventum Corp (SOLV) | United States | $15.085B | 9.16 |
| Penumbra Inc (PEN) | United States | $12.596B | 77.33 |
| BAXTER INTERNATIONAL INC (BAX) | United States | $12.139B | -10.35 |
| GLOBUS MEDICAL INC (GMED) | United States | $9.977B | 20.03 |
| INSULET CORP (PODD) | United States | $9.420B | 28.12 |
| GLAUKOS Corp (GKOS) | United States | $9.135B | -43.73 |
| MiniMed Group, Inc. (MMED) | United States | $5.748B | -16.85 |
| MERIT MEDICAL SYSTEMS INC (MMSI) | United States | $5.212B | 28.44 |
| TELEFLEX INC (TFX) | United States | $5.093B | -5.44 |